Profile data is unavailable for this security.
About the company
Precigen, Inc. is a dedicated discovery and clinical-stage biopharmaceutical company advancing gene and cell therapies. The Company’s proprietary technology platforms develops product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company operates through two segments: Biopharmaceuticals and Exemplar. Biopharmaceuticals segment is primarily comprised of the Company's legal entities of Precigen and ActoBio, as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. Exemplar segment is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar (Exemplar), its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
- Revenue in USD (TTM)5.44m
- Net income in USD-96.91m
- Incorporated2004
- Employees202.00
- LocationPrecigen Inc20374 SENECA MEADOWS PARKWAYGERMANTOWN 20876United StatesUSA
- Phone+1 (301) 556-9900
- Websitehttps://precigen.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revance Therapeutics Inc | 236.65m | -313.72m | 279.92m | 597.00 | -- | -- | -- | 1.18 | -3.61 | -3.65 | 2.71 | -0.945 | 0.4482 | 1.87 | 10.46 | 396,390.30 | -59.42 | -55.55 | -69.02 | -63.20 | 69.11 | -- | -132.57 | -304.96 | 4.64 | -30.79 | 1.30 | -- | 76.55 | 128.84 | 9.10 | -- | -0.3022 | -- |
Procaps Group SA | 414.10m | 52.20m | 282.06m | 5.50k | 4.80 | 7.16 | 4.05 | 0.6812 | 0.5209 | 0.5209 | 4.16 | 0.3491 | 0.854 | 1.87 | 3.38 | 75,290.18 | 10.77 | -- | 19.01 | -- | 55.04 | -- | 12.61 | -- | 0.9861 | -- | 0.8829 | -- | 0.0434 | -- | 142.18 | -- | -- | -- |
Alimera Sciences Inc | 90.22m | -22.66m | 289.18m | 159.00 | -- | 7.11 | -- | 3.21 | -1.57 | -1.57 | 2.42 | 0.7762 | 0.8989 | 7.11 | 3.43 | 567,415.10 | -21.34 | -19.08 | -25.84 | -27.37 | 86.52 | 86.80 | -23.74 | -19.55 | 2.51 | -0.0756 | 0.6323 | -- | 49.19 | 11.62 | -18.14 | -- | 236.53 | -- |
Xeris Biopharma Holdings Inc | 171.36m | -64.40m | 308.37m | 377.00 | -- | -- | -- | 1.80 | -0.4648 | -0.4648 | 1.24 | -0.0619 | 0.5209 | 0.838 | 5.02 | 454,525.20 | -19.58 | -43.60 | -25.58 | -56.57 | 82.90 | 78.23 | -37.58 | -143.08 | 1.81 | -2.04 | 1.04 | -- | 48.68 | 131.50 | 34.23 | -- | 8.43 | -- |
Verrica Pharmaceuticals Inc | 8.91m | -80.74m | 318.15m | 100.00 | -- | 210.98 | -- | 35.70 | -1.75 | -1.75 | 0.1929 | 0.0356 | 0.1321 | -- | 2.33 | 89,130.00 | -119.66 | -55.75 | -142.98 | -78.33 | 79.63 | -- | -905.83 | -754.94 | 3.04 | -21.71 | 0.9678 | -- | -43.27 | -- | -173.59 | -- | 5.65 | -- |
Scilex Holding Co | 47.05m | -160.60m | 326.14m | 106.00 | -- | -- | -- | 6.93 | -1.28 | -1.28 | 0.3905 | -1.79 | 0.5307 | 5.53 | 1.92 | 448,047.60 | -121.78 | -- | -- | -- | 66.14 | -- | -229.47 | -- | 0.1356 | -12.49 | -- | -- | 22.90 | -- | -614.67 | -- | -- | -- |
Jasper Therapeutics Inc | 0.00 | -63.93m | 335.05m | 45.00 | -- | 2.96 | -- | -- | -5.60 | -5.60 | 0.00 | 7.51 | 0.00 | -- | -- | 0.00 | -48.30 | -- | -51.58 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.06 | -- | -- | -- |
Bio Essence Corp | 551.51k | -812.66k | 369.71m | 12.00 | -- | -- | -- | 670.37 | -0.0225 | -0.0157 | 0.015 | -0.0378 | 0.4912 | -- | 1.53 | 45,959.17 | -72.37 | -46.34 | -- | -- | 31.29 | 33.89 | -147.35 | -111.21 | -- | -47.73 | 3.39 | -- | -11.27 | -10.94 | -52.03 | -- | -48.19 | -- |
Precigen Inc | 5.44m | -96.91m | 371.06m | 202.00 | -- | 3.79 | -- | 68.22 | -0.3896 | -0.3896 | 0.0219 | 0.3877 | 0.0289 | -- | 4.12 | 26,925.74 | -51.49 | -31.50 | -64.42 | -38.63 | -4.19 | 44.00 | -1,781.73 | -232.32 | -- | -- | 0.00 | -- | -76.87 | -47.16 | -20.22 | -- | -48.30 | -- |
Anika Therapeutics Inc | 169.26m | -76.83m | 376.05m | 357.00 | -- | 1.80 | -- | 2.22 | -5.24 | -5.24 | 11.54 | 14.07 | 0.5616 | 1.42 | 5.40 | 474,120.40 | -25.49 | -5.41 | -28.16 | -5.87 | 61.96 | 60.70 | -45.39 | -12.60 | 3.85 | -- | 0.00 | -- | 6.67 | 9.56 | -456.34 | -- | 3.11 | -- |
Emergent Biosolutions Inc | 1.19bn | -565.30m | 395.11m | 1.60k | -- | 0.5951 | -- | 0.3333 | -10.87 | -10.87 | 22.86 | 12.67 | 0.4988 | 1.99 | 6.09 | 740,875.00 | -23.79 | -2.94 | -38.89 | -3.66 | 41.19 | 53.24 | -47.69 | -5.95 | 0.5538 | 0.0636 | 0.5771 | -- | -6.10 | 6.05 | -259.40 | -- | -4.29 | -- |
Theravance Biopharma Inc | 61.51m | -44.77m | 413.87m | 99.00 | -- | 2.02 | -- | 6.73 | -0.861 | -0.861 | 1.19 | 4.22 | 0.1352 | -- | 4.57 | 621,313.10 | -9.84 | -40.51 | -10.39 | -48.50 | -- | -- | -72.78 | -305.27 | -- | -- | 0.00 | -- | 11.84 | -0.9956 | 40.54 | -- | -19.24 | -- |
Esperion Therapeutics Inc | 229.74m | -86.51m | 447.13m | 240.00 | -- | -- | -- | 1.95 | -1.00 | -1.00 | 1.76 | -1.57 | 0.7353 | 0.7415 | 5.05 | 957,250.00 | -27.69 | -69.45 | -47.42 | -101.81 | 81.85 | -- | -37.65 | -147.44 | 1.78 | -0.6581 | -- | -- | 54.14 | -- | 10.45 | -- | -- | -- |
Eyepoint Pharmaceuticals Inc | 50.02m | -78.92m | 448.97m | 121.00 | -- | 1.72 | -- | 8.98 | -1.83 | -1.83 | 1.17 | 5.01 | 0.2068 | 1.14 | 7.44 | 413,380.20 | -32.62 | -40.44 | -40.06 | -47.79 | 90.50 | 83.45 | -157.77 | -186.23 | 5.01 | -- | 0.00 | -- | 11.14 | -- | 30.77 | -- | -- | -- |
Avid Bioservices Inc | 136.74m | -18.26m | 488.79m | 365.00 | -- | 2.71 | -- | 3.57 | -0.2888 | -0.2888 | 2.17 | 2.84 | 0.302 | 3.18 | 4.89 | 374,616.40 | -4.03 | 10.70 | -6.13 | 15.18 | 7.47 | 22.72 | -13.35 | 25.86 | 0.3097 | -2.71 | 0.4548 | 0.00 | 24.81 | 22.72 | -99.80 | -- | 82.98 | -- |
Holder | Shares | % Held |
---|---|---|
Patient Capital Management LLC (Invt Mgmt)as of 31 Mar 2024 | 17.45m | 6.91% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 9.29m | 3.68% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 6.67m | 2.64% |
Geode Capital Management LLCas of 31 Mar 2024 | 3.03m | 1.20% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 2.83m | 1.12% |
Iridian Asset Management LLCas of 31 Mar 2024 | 2.09m | 0.83% |
D. E. Shaw & Co. LPas of 31 Mar 2024 | 1.78m | 0.71% |
Millennium Management LLCas of 31 Mar 2024 | 1.37m | 0.54% |
JPMorgan Asset Management (UK) Ltd.as of 31 Mar 2024 | 1.18m | 0.47% |
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 1.08m | 0.43% |